MedPath
Found 3 clinical trials|View Analysis
Sort by:

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Phase 2
Completed
Conditions
Bladder Cancer
Interventions
Drug: induction cisplatin
Drug: induction gemcitabine
Drug: induction 5-fluorouracil
Radiation: Induction QD radiation therapy
Radiation: Induction BID radiation therapy
Radiation: Consolidation QD radiation therapy
Radiation: Consolidation BID radiation therapy
Drug: consolidation gemcitabine
Drug: consolidation 5-fluorouracil
Drug: consolidation cisplatin
Procedure: Post-Induction Chemoradiotherapy Endoscopic Response Evaluation
Procedure: radical cystectomy
Drug: adjuvant gemcitabine
Drug: adjuvant cisplatin
First Posted Date
2008-10-22
Last Posted Date
2022-06-15
Lead Sponsor
Radiation Therapy Oncology Group
Target Recruit Count
70
Registration Number
NCT00777491
Locations
🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States

🇺🇸

Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia, United States

and more 8 locations

UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide

Phase 3
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Interim/Maintenance Dexamethasone
Drug: Induction/Consolidation Dexamethasone
Drug: Induction/Consolidation Cisplatin
Drug: Induction/Consolidation Adriamycin
Drug: InductionConsolidation Cyclophosphamide
Drug: Induction/Consolidation Etoposide
Drug: Induction Pegfilgrastim
Drug: Transplant 1 Dexamethasone
Drug: Transplant 1 Cisplatin
Drug: Transplant 1 Adriamycin
Drug: Transplant 1 Cyclophosphamide
Drug: Transplant 1 Etoposide
Drug: Transplant 1 Melphalan
Drug: Transplant 1 and 2 Pegfilgrastim
Procedure: Autologous Peripheral Blood Stem Cell Transplant (ASCT)
Drug: Transplant 2 Carmustine
Drug: Transplant 2 Etoposide
Drug: Transplant 2 Cytarabine
Drug: Transplant 2 Melphalan
Drug: Transplant 2 Dexamethasone
Drug: Transplant 1 and 2 Bortezomib
Drug: Transplant 1 and 2 Thalidomide
First Posted Date
2007-12-14
Last Posted Date
2017-11-20
Lead Sponsor
University of Arkansas
Target Recruit Count
20
Registration Number
NCT00574080
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients

Phase 2
Terminated
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Drug: docetaxel and cisplatin
Radiation: radiotherapy
First Posted Date
2005-12-30
Last Posted Date
2009-12-23
Lead Sponsor
Sanofi
Target Recruit Count
14
Registration Number
NCT00271323
Locations
🇫🇷

Sanofi-Aventis, Paris, France

© Copyright 2025. All Rights Reserved by MedPath